The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

While immunotherapies like Keytruda have transformed the treatment of certain cancers ... PESG Research is a digital commentary brand, offering coverage and exploration into companies and sectors in ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...

The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...

Health care stocks lagged the S&P 500 in 2023, but they can often be a solid defensive play in an uncertain economy. People don't typically reduce their prescription drug purchases or put ...

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer conference in San Diego, US.